| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T302 |
0-95 |
Sentence |
denotes |
IgG4 mAbs have been similarly engineered to eliminate their interaction with FcγRI and FcγRIIb. |
| T303 |
96-370 |
Sentence |
denotes |
The IgG4 anti‐PD‐1 antibody tislelizumab has had its FcγR contact residues in the lower hinge E233, F234, L235 substituted with the equivalent residues of IgG2 P, V, A (E233P, F234V, L235A) as well as the additional D265A mutation which disrupts a major FcγR contact in CH2. |
| T304 |
371-588 |
Sentence |
denotes |
It also has substitutions in the core hinge S228P and the CH3 L309V and R409K to stabilize the H‐chain disulfides and CH3 interactions, respectively, thereby preventing half‐Ig exchange characteristic of natural IgG4. |
| T305 |
589-693 |
Sentence |
denotes |
Collectively, these modifications create a stable IgG4 with no FcγR binding nor complement activation.17 |
